All Articles
-
RevolKa Director & CSO Prof. Mitsuo Umetsu (Tohoku-Univ.) and Team Announce New AI-Driven Method toAccelerate Discovery of Highly Functional Antibodies
-
RevolKa Reimagines Antibody Engineering with “RevoAb®”
-
Corporate Website Renewal Notice
-
Poster presentation at “Antibody engineering & therapeutics Asia”
-
【Update】We Will Exhibit at “Global Startup EXPO 2025”
-
‘RevoAb™’: A New Service for Antibody Developability Engineering
-
We Will Exhibit at “PEGS Europe”
-
We Will Exhibit at “Antibody Engineering 2025″
-
We Will Exhibit at “Global Startup EXPO 2025”
-
RevolKa Ltd. Joins Research and Development Program for Innovative Biologics Funded by the Japanese Agency for Medical Research and Development (AMED)